Physician profile
Michael B Harris
NPI 1396849691
$2,365.25
in general payments reported to CMS, 2019-2025
23 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $126 · 2021: $270 · 2022: $182 · 2023: $341 · 2024: $279 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $421.62 | 2019-2025 | |
| Abbvie INC. | $356.65 | 2021-2024 | |
| Novo Nordisk INC | $280.69 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $271.52 | 2019-2024 | Airsupra |
| Amgen INC. | $124.77 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $109.33 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $99.08 | 2019-2023 | Spravato |
| Endogastric Solutions, INC | $85.67 | 2019 | |
| Lilly USA, LLC | $84.92 | 2019-2023 | Jardiance |
| Allergan, INC. | $78.98 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.56 | 2019 | |
| Dexcom, INC. | $62.44 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $62.34 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.58 | 2019 | |
| Amarin Pharma, INC. | $46.52 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $30.57 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.22 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.81 | 2019 | |
| Aytu Biopharma, INC. | $18.44 | 2019 | |
| Abbott Laboratories | $17.61 | 2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $14.24 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.97 | 2021 | |
| Boston Scientific Corporation | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.